Astec LifeSciences financials

·ChemicalsChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹72.0cr−2.3% on Q2 FY26
Net profit
−₹37.4cr−₹24.4 cr in Q2 FY26
EBITDA margin
−27.5%−18.4 pts on Q2 FY26
EPS
−₹16.79−₹11.35 in Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue72.073.7−2.3%
EBITDA−19.8−6.7—
EBITDA margin−27.5%−9.1%−18.4 pts
Profit before tax−37.4−24.4—
Net profit−37.4−24.4—
EPS−₹16.79−₹11.35—

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹72.0 crNet profit₹−37.4 crNet margin−51.9%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1,295————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.110.00.60.50.5
0.30.30.30.20.2
449449555494341
1,744————
439448381458628
—+17.5%−16.8%−27.1%—
−7.3−4.5−66.2−5.976.3
−1.7%−1.0%−17.4%−1.3%12.1%
−52.5−49.4−110−42.242.6
−79.5−80.9−135−46.925.6
−18.1%−18.1%−35.3%−10.2%4.1%
−₹35.71−₹36.31−₹60.48−₹21.06₹11.47
—+40.0%−187.1%−283.6%—
—−80.7−8.410.274.7
—−5.5−21.8−135−117
−86.2−86.2−30.2−125−42.6
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ASTEC₹581.05

Astec LifeSciences Limited

· Chemicals
₹ CrorePeersPUNJABCHEMMOLIPLINSECTICIDDHARMAJBHARATRASADVANCEHERANBAMcap ₹1,295 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————1,294.7
- Cash, Equiv & ST Investments0.50.50.610.00.1
+ Minority Interest0.20.20.30.30.3
+ Total Debt341.2493.9554.5448.9448.9
Enterprise Value————1,743.8
Revenue628.2458.2381.3448.1438.9
Growth %, YoY—-27.1-16.8+17.5—
EBITDA76.3-5.9-66.2-4.5-7.3
Margin %12.14-1.29-17.36-1.01-1.67
EBIT42.6-42.2-109.9-49.4-52.5
Net Income25.6-46.9-134.7-80.9-79.5
Margin %4.07-10.23-35.33-18.05-18.12
EPS, Adj (current shares)11.47-21.06-60.48-36.31-35.71
Growth %, YoY—-283.6-187.1+40.0—
Cash from Operations74.710.2-8.4-80.7—
Capital Expenditures-117.3-135.5-21.8-5.5—
Free Cash Flow-42.6-125.3-30.2-86.2-86.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Astec LifeSciences financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Astec LifeSciences (NSE: ASTEC) had a market capitalisation of ₹1,216 crore at the 29 October 2026 close (₹545.55 a share) and a price-to-book ratio of 3.63. In FY26 its consolidated net loss was ₹80.9 crore on revenue of ₹448 crore; in Q2 FY27 (July–September 2026) it was a loss of ₹37.4 crore. Its debt-to-equity ratio was 0.99 on 30 September 2026. Promoters held 71.96% of the shares on 30 September 2026.

Share price used
₹545.55 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Astec LifeSciences at a glance · consolidated

Market cap
₹1,216 Crat ₹545.55 · 29 Oct close
PE ratio
n/aloss over the last 4 quarters
Price to book (PB)
3.63book value ₹150.24 a share
ROE (FY26)
−25.9%+18.7 pts vs FY25ROCE −10.3%
Debt to equity
0.99net debt ₹329 Cr
Promoter holding
71.96%unchanged vs 30 Jun 202630 September 2026
Net worth
₹335 Cr−19.1% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
−₹86.2 Cr
EPS (FY26)
−₹37.79

Questions

What is the Astec LifeSciences PE ratio today?

Astec LifeSciences' PE ratio is not meaningful at the 29 October 2026 close: its consolidated net profit over the last four quarters (Q3 FY26 to Q2 FY27) was a loss of ₹79.6 crore, and a price-to-earnings ratio needs positive earnings. Its market capitalisation was ₹1,216 crore at ₹545.55 a share.

What is the Astec LifeSciences net worth?

Astec LifeSciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹335 crore on 30 September 2026, down 19.1% from ₹414 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,216 crore at the 29 October 2026 close.

What is the Astec LifeSciences book value per share?

Astec LifeSciences' book value per share was ₹150.24 on 30 September 2026: shareholders' equity of ₹335 crore divided by the 2.23 crore shares in issue, down 19.1% from ₹185.77 a year earlier. The share price at the 29 October 2026 close was ₹545.55.

What is the Astec LifeSciences PB ratio (price to book value)?

Astec LifeSciences' price-to-book (PB) ratio is 3.63 at the 29 October 2026 close: a market capitalisation of ₹1,216 crore divided by shareholders' equity (book value) of ₹335 crore on 30 September 2026. That is a book value of ₹150.24 per share against a share price of ₹545.55.

What is the Astec LifeSciences ROE and ROCE?

In FY26, Astec LifeSciences' return on equity (ROE) was −25.9% and its return on capital employed (ROCE) was −10.3%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was −44.6% and ROCE −20.1%.

What is the Astec LifeSciences shareholding pattern?

On 30 September 2026, Astec LifeSciences' shares were held by promoters 71.96%, foreign portfolio investors (FII/FPI) 0.03%, domestic institutions (DII) 3.34% (including mutual funds at 3.02%) and retail and other non-institutional investors 24.67%. Over the year, FII holding was up 0.03 percentage points from 0.00% and DII holding was down 0.67 percentage points from 4.01%.

What is the Astec LifeSciences market cap?

Astec LifeSciences' market capitalisation was ₹1,216 crore at the 29 October 2026 close: 2.23 crore shares at ₹545.55 each.

Is Astec LifeSciences debt free?

No. Astec LifeSciences had borrowings of ₹331 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.99. Its cash and current investments were ₹1.5 crore, so its net debt was ₹329 crore.

What is the Astec LifeSciences EPS?

Astec LifeSciences' basic earnings per share (EPS) were −₹37.79 in FY26, against −₹68.71 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to −₹35.71.

What is the Astec LifeSciences debt to equity ratio?

Astec LifeSciences' debt-to-equity ratio was 0.99 on 30 September 2026: borrowings of ₹331 crore against total equity of ₹335 crore. A year earlier, on 30 September 2025, it was 0.89.

What is the Astec LifeSciences promoter holding?

Promoters held 71.96% of Astec LifeSciences on 30 September 2026, unchanged from the previous quarter and down 0.46 percentage points from 72.42% a year earlier, according to the shareholding pattern filed with NSE.

What is the Astec LifeSciences free cash flow?

In FY26, Astec LifeSciences generated ₹80.7 crore of cash from operations and spent ₹5.5 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹86.2 crore. In FY25 it was −₹30.2 crore.

What are the Astec LifeSciences latest quarterly results?

Astec LifeSciences' latest results are for Q2 FY27 (July–September 2026), filed on 26 October 2026: consolidated net loss ₹37.4 crore, wider than the loss of ₹24.4 crore in Q2 FY26; revenue from operations ₹72 crore, down 2.3% year on year.

What is the Astec LifeSciences revenue and profit in FY26?

In FY26 (April 2025–March 2026), Astec LifeSciences' consolidated net loss was ₹80.9 crore, narrower than the loss of ₹135 crore in FY25, on revenue from operations of ₹448 crore (up 17.5%).

When are the Astec LifeSciences next results?

Astec LifeSciences has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

How does Astec LifeSciences compare with its peers?

On FY26 consolidated figures, against Punjab Chemicals & Crop Protection, Meghmani Organics and India Pesticides: Astec LifeSciences' operating margin of −11.0% is the lowest of the four (Punjab Chemicals & Crop Protection 8.7%, Meghmani Organics 2.6%, India Pesticides 14.4%; peer average 8.6%); its return on equity of −25.9% is the lowest of the four (Punjab Chemicals & Crop Protection 16.2%, Meghmani Organics 1.9%, India Pesticides 12.6%; peer average 10.2%); its revenue growth over three years of −10.7% a year is the lowest of the four (Punjab Chemicals & Crop Protection 0.8% a year, Meghmani Organics −5.2% a year, India Pesticides 6.1% a year; peer average 0.6% a year).

Astec LifeSciences vs Punjab Chemicals & Crop Protection: how do they compare?

In FY26, Astec LifeSciences earned net profit of ₹80.9 crore on revenue of ₹448 crore, against ₹64 crore on ₹1,030 crore for Punjab Chemicals & Crop Protection. Astec LifeSciences' operating margin was −11.0% (Punjab Chemicals & Crop Protection 8.7%) and its return on equity −25.9% (Punjab Chemicals & Crop Protection 16.2%). At the 29 October 2026 close, Astec LifeSciences' market capitalisation was ₹1,216 crore against ₹1,166 crore for Punjab Chemicals & Crop Protection.

Where do these Astec LifeSciences figures come from?

From Astec LifeSciences' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.